Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B
暂无分享,去创建一个
J. Jakana | Zhilei Chen | H. Feng | Hua Yu | Yongrong Zhang | Junjie Zhang | Rudo L. Simeon | A. Chamoun-Emanuelli | Zeyu Peng | Mengqiu Jiang | R. Meng | Ana M. Chamoun-Emanuelli
[1] K. Lam,et al. Structural basis for recognition of frizzled proteins by Clostridium difficile toxin B , 2018, Science.
[2] H. Feng,et al. The role of purified Clostridium difficile glucosylating toxins in disease pathogenesis utilizing a murine cecum injection model. , 2017, Anaerobe.
[3] H. Binz,et al. Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate , 2017, mAbs.
[4] D. Lacy,et al. Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants , 2017, The Journal of Biological Chemistry.
[5] D. Gerding,et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection , 2017, The New England journal of medicine.
[6] Asher Mullard. FDA approves antitoxin antibody , 2016, Nature Reviews Drug Discovery.
[7] Asher Mullard. EMA opens its data vaults , 2016, Nature Reviews Drug Discovery.
[8] A. Brass,et al. Frizzled are colonic epithelial receptors for Clostridium difficile toxin B , 2016, Nature.
[9] A. Chit,et al. Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study , 2016, BMC Infectious Diseases.
[10] Saul Tzipori,et al. A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection , 2016, Clinical and Vaccine Immunology.
[11] C. Nykiforuk,et al. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model , 2016, PloS one.
[12] Klaus Schulten,et al. Advances in the molecular dynamics flexible fitting method for cryo-EM modeling. , 2016, Methods.
[13] D. Giedroc,et al. Crystal structure of Clostridium difficile toxin A , 2016, Nature Microbiology.
[14] Mark Bates,et al. Nanobodies: site-specific labeling for super-resolution imaging, rapid epitope-mapping and native protein complex isolation , 2015, eLife.
[15] N. Grigorieff,et al. CTFFIND4: Fast and accurate defocus estimation from electron micrographs , 2015, bioRxiv.
[16] Nikolaus Grigorieff,et al. Measuring the optimal exposure for single particle cryo-EM using a 2.6 Å reconstruction of rotavirus VP6 , 2015, eLife.
[17] Jinsong Sheng,et al. Identification of an epithelial cell receptor responsible for Clostridium difficile TcdB-induced cytotoxicity , 2015, Proceedings of the National Academy of Sciences.
[18] Ed J. Kuijper,et al. Clostridium difficile infection , 2016, Nature Reviews Disease Primers.
[19] J. Meek,et al. Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.
[20] J. Larabee,et al. Exposure of Neutralizing Epitopes in the Carboxyl-terminal Domain of TcdB Is Altered by a Proximal Hypervariable Region* , 2015, The Journal of Biological Chemistry.
[21] H. Rohde,et al. Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT , 2015, Scientific Reports.
[22] D. Lyras,et al. Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations. , 2015, Future microbiology.
[23] Andreas Plückthun,et al. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. , 2015, Annual review of pharmacology and toxicology.
[24] H. Feng,et al. Chondroitin sulfate proteoglycan 4 functions as the cellular receptor for Clostridium difficile toxin B , 2014, Cell Research.
[25] Yang Zhang,et al. The I-TASSER Suite: protein structure and function prediction , 2014, Nature Methods.
[26] A. Therien,et al. Mechanisms of Protection against Clostridium difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab , 2014, Infection and Immunity.
[27] A. Therien,et al. Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by In Vitro Neutralization and Epitope Modeling , 2014, Antimicrobial Agents and Chemotherapy.
[28] A. Plückthun,et al. Protein interference applications in cellular and developmental biology using DARPins that recognize GFP and mCherry , 2014, Biology Open.
[29] M. Grütter,et al. Specific targeting of human caspases using designed ankyrin repeat proteins , 2014, Biological chemistry.
[30] D. Schmidt,et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. , 2014, The Journal of infectious diseases.
[31] C. Briand,et al. Combined inhibition of caspase 3 and caspase 7 by two highly selective DARPins slows down cellular demise. , 2014, The Biochemical journal.
[32] A. Therien,et al. Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray Crystallography , 2014, The Journal of Biological Chemistry.
[33] A. Plückthun,et al. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension. , 2013, Bioconjugate chemistry.
[34] A. Steven,et al. One number does not fit all: mapping local variations in resolution in cryo-EM reconstructions. , 2013, Journal of structural biology.
[35] M. Vogel,et al. Designed Ankyrin Repeat Proteins: A New Approach to Mimic Complex Antigens for Diagnostic Purposes? , 2013, PloS one.
[36] C. Briand,et al. Specific inhibition of caspase-3 by a competitive DARPin: molecular mimicry between native and designed inhibitors. , 2013, Structure.
[37] Sjors H.W. Scheres,et al. RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.
[38] Fernanda C. Lessa,et al. Current Status of Clostridium difficile Infection Epidemiology , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] Shaoxia Chen,et al. Prevention of overfitting in cryo-EM structure determination , 2012, Nature Methods.
[40] Andreas Plückthun,et al. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. , 2011, Journal of molecular biology.
[41] A. Plückthun,et al. Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling* , 2011, The Journal of Biological Chemistry.
[42] J. Tanha,et al. Neutralization of Clostridium difficile Toxin A with Single-domain Antibodies Targeting the Cell Receptor Binding Domain* , 2011, The Journal of Biological Chemistry.
[43] M. Vogel,et al. DARPins against a functional IgE epitope. , 2010, Immunology letters.
[44] H. Moch,et al. Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer , 2010, Modern Pathology.
[45] D. Lacy,et al. Structural organization of the functional domains of Clostridium difficile toxins A and B , 2010, Proceedings of the National Academy of Sciences.
[46] M. P. Bauer,et al. The Changing Epidemiology of Clostridium difficile Infections , 2010, Clinical Microbiology Reviews.
[47] M. Vogel,et al. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. , 2009, Journal of molecular biology.
[48] A. Plückthun,et al. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins , 2009, Molecular Cancer Therapeutics.
[49] A. Plückthun,et al. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. , 2008, Journal of molecular biology.
[50] Torsten Schwede,et al. The SWISS-MODEL Repository and associated resources , 2008, Nucleic Acids Res..
[51] M. Oka,et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. , 2008, Neoplasia.
[52] Klaus Aktories,et al. Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity* , 2007, Journal of Biological Chemistry.
[53] Andreas Plückthun,et al. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. , 2007, Structure.
[54] S. Tenzer,et al. Autocatalytic cleavage of Clostridium difficile toxin B , 2007, Nature.
[55] C. Briand,et al. Drug Export Pathway of Multidrug Exporter AcrB Revealed by DARPin Inhibitors , 2006, PLoS biology.
[56] Andreas Plückthun,et al. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display , 2006, Nature Biotechnology.
[57] A. Plückthun,et al. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. , 2006, Protein engineering, design & selection : PEDS.
[58] David N Mastronarde,et al. Automated electron microscope tomography using robust prediction of specimen movements. , 2005, Journal of structural biology.
[59] Andreas Plückthun,et al. Intracellular Kinase Inhibitors Selected from Combinatorial Libraries of Designed Ankyrin Repeat Proteins* , 2005, Journal of Biological Chemistry.
[60] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[61] A. Plückthun,et al. High-affinity binders selected from designed ankyrin repeat protein libraries , 2004, Nature Biotechnology.
[62] Andreas Plückthun,et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. , 2003, Journal of molecular biology.
[63] J. Trinder,et al. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome , 2003, Intensive Care Medicine.
[64] Klaus Aktories,et al. The complete receptor-binding domain of Clostridium difficile toxin A is required for endocytosis. , 2003, Biochemical and biophysical research communications.
[65] R. Benz,et al. Low pH-induced Formation of Ion Channels by Clostridium difficile Toxin B in Target Cells* , 2001, The Journal of Biological Chemistry.
[66] F. Barbut,et al. Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.
[67] J. Ballard,et al. pH-Induced Conformational Changes inClostridium difficile Toxin B , 2000, Infection and Immunity.
[68] W Chiu,et al. EMAN: semiautomated software for high-resolution single-particle reconstructions. , 1999, Journal of structural biology.
[69] C. von Eichel-Streiber,et al. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. , 1997, FEMS microbiology letters.
[70] M. Wilm,et al. The Enterotoxin from Clostridium difficile (ToxA) Monoglucosylates the Rho Proteins(*) , 1995, The Journal of Biological Chemistry.
[71] M. Mann,et al. Glucosylation of Rho proteins by Clostridium difficile toxin B , 1995, Nature.
[72] W. Stamm,et al. Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.
[73] J. Dubochet,et al. Cryo-electron microscopy of vitrified specimens , 1988, Quarterly Reviews of Biophysics.
[74] I. Florin,et al. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. , 1986, Microbial pathogenesis.
[75] J. Northrop. CRYSTALLINE PEPSIN : I. ISOLATION AND TESTS OF PURITY , 1930 .
[76] H. Morrison. Chymotrypsin , 2021, Enzyme Active Sites and their Reaction Mechanisms.
[77] Mandy Berg,et al. Handbook Of Proteolytic Enzymes , 2016 .
[78] Boping Zhou,et al. BMC Microbiology BioMed Central Methodology article Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium , 2008 .
[79] J Bernard Heymann,et al. Bsoft: image processing and molecular modeling for electron microscopy. , 2007, Journal of structural biology.
[80] J. Northrop,et al. CRYSTALLINE TRYPSIN I . ISOLATION AND TESTS OF PURITY BY JOHN H. NORTHROP AND M. KUNITZ , 2003 .